We are an accredited investor platform targeting companies at the cross section of science and technology. Bioverge provides founders access to capital to help them push the boundaries of human healthcare, while democratizing the investing process for accredited investors in the $2 trillion healthcare market.
it’s a big deal on a very deep, fundamental level, in terms of thinking about the meaning of life. At a much more mundane business level, there’s clearly a huge market opportunity here…Bio is therefore an area where there’s a real chance to change the world … but also a chance for really great financial returns as well."
- Vijay Pande, General Partner and Manager of Andreessen Horowitz’ new $250 million dedicated bio fund “When Software Eats Bio.” April 2016. View source.
All startups must have secured funding from a validated third party, this can include: accelerator/incubator, VC, strategic partner, professional angel group, or federal agency. This gate allows for an additional level of scientific and technical validation by experts prior to Bioverge’s diligence process.
We utilize a quantitative decision-analysis model — originally derived from the OS Fund - to help assess the risk-adjusted returns associated with each investment. We combine this with input from our network of scientific, technical, and professional investors to create a rigorous and dynamic feedback loop.
Only deals that pass our Investment Committee screening process are listed on our site and available for investors.
As an active investor myself I found it difficult to source, diligence, and invest in novel science companies working on projects that mattered to me. There was no cohesive ecosystem that focused on the skills necessary to appropriately assess the viability of the opportunity. Bioverge was created to remove that hurdle. I believe health matters, happiness matters, families matter and we as a community should be able to achieve both a financial upside and social benefit from investing in technologies that we care about.